Hepatocellular damage is a key driver of chronic liver disease progression, linked to various causes, including NAFLD and NASH, ASH, hepatitis C, and hepatitis B. Serum L-FABP levels are used to monitor liver damage in NAFLD, fibrosis in NASH, and HCV infection [20]. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.